PPD Names VPs for North America and Asia(retain keypersonnel; competition within ...),Health
Navigation Links
PPD Names VPs for North America and Asia
Date:10/10/2007
retain key personnel; competition within the outsourcing industry; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; success in sales growth; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
Contacts
Media:
Louise Caudle
+919 456 4467
Analysts/Investors:
Steve Smith
+910 558 7585
'/>"/>
| SOURCE PPD, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus
2. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
3. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
4. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
5. Health Minister Wants Names of Uncooperative Hospital Consultants
6. Chinese PLA Names Bogus Army Medical Bodies Selling Fake Drugs
7. Over 50 Vietnamese Girls Faint Due to Mass Hysteria
8. All U.S. States To Begin Names-Based Reporting of HIV Cases by End of 2007
9. Rajasthan Directs Doctors to Prescribe Medicines by Generic Names
10. Rise In Obesity Among North Qeenslanders
11. Northfield Labs Receives FDA Comments
Post Your Comments:
(Date:1/8/2009)..., Results of St. Jude study could shape new treat...., Jan. 8 Scientists at...trated a more effective treatment for bacterial pn...ntibiotics clindamycin and azithromycin, which kil...are more effective than a standard first-line trea...
(Date:1/8/2009)...eview says it lowered bad cholesterol more effecti...althDay News) -- After nearly a year of review, U....ted the continued use of the controversial cholest... Drug Administration said there was no significant...tients taking Vytorin and patients taking the drug...
(Date:1/8/2009)..., BETHESDA, Md., Jan. 8 /PRNewswire-FirstCall/ -...pleased to announce that throughout the fourth qua..., Orthotics Center, Rocky Mountain Orthotic-Prosth...Services, Inc., First Coast Orthotics & Prosth.... These acquisitions add patient care centers to e...
(Date:1/8/2009)..., SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall...ounced that David Hung, M.D., president and chief,...l J.P. Morgan Healthcare,Conference on Wednesday,...tin,St. Francis Hotel in San Francisco. , ...d its clinical,development programs for Dimebon f...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2[0] Study Finds More Effective Treatment for Pneumonia Following Influenza[0] FDA Backs Cholesterol Drug Vytorin[0] Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue[0] Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
...management program cuts diabetes risk and is more ...s index (BMI) in overweight children. A family-b...chers at Yale School of Medicine was more successf...MI and insulin sensitivity than traditional clinic...
...rier cities like the Indian capital but also modif... warns a UN report released Wednesday. "Much of ...al areas from which they were first displaced," sa...lation 2007' report of the United Nations Populati...
...in Pakistan, evoking mixed reactions. <brThe...something extraordinary. Then the Lahore High Cou...comes as a pleasant surprise is the decision of th...e Court to release them on bail and hear their ap...
...ua, today welcomed Labors preventative health care... addressing Australias future health needs. Dr Ca...s ageing population and the increasing incidence o...including among younger people, will place great s...
Other Medicine News:Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2Health News:Same Sex Pair Get Relief in Pakistan 2Health News:Labor's Preventive Health Care Policy Looks to Address Future Needs 2(Date:1/6/2009)... In recent controlled studies cond...is , scientists found that the patented ingredient...only proven ingredient to increase levels of nitri... nitrate/nitrate (NOx) in human subjects. , , N...ncrease in blood flow to the skeletal muscles. Th...
(Date:1/6/2009).... 6 Cequent Pharmaceuticals, a pio...er RNAi-based treatments to prevent and treat huma... completed a successful toxicology study of its ca...erapeutic targeting the primary oncogene (beta-cat...is). FAP is an inherited gastrointestinal disease ...
(Date:1/5/2009)...Newswire/ -- Cylene Pharmaceuticals announced toda...f its oral CK2 protein kinase inhibitor, CX-4945, ...s disease, or multiple myeloma. The primary endpoi...ation of safety, tolerance and PK properties of CX... II trials. In addition, multiple mechanism-relate...
(Date:1/3/2009)..., , ROSEMONT, Ill., Jan. 2 /PRNewswire-USNewswi...ng technology providing an increasing number of cl...k pain according to an article in the January 2009...rthopaedic Surgeons ( http://www.jaaos.org/ ). It...ditional technical developments will allow MRI to ...
Breaking Medicine Technology:US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3Atria Bills Get Support From Assisted Living Residents Family Members Senior Groups 13314 1Atria Bills Get Support From Assisted Living Residents Family Members Senior Groups 13314 2Unfavorable ocean conditions likely cause of low 2007 salmon returns along West Coast 2381 1Unfavorable ocean conditions likely cause of low 2007 salmon returns along West Coast 2381 2AMA Asks Patients 3A Do You Know Whats in Your Medicine Cabinet 3F 13312 1AMA Asks Patients 3A Do You Know Whats in Your Medicine Cabinet 3F 13312 2mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 1mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 2mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 3mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 4mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 5mtvU 26 The Jed Foundation Go Beyond March Madness Spring Break 26 5th Anniversary of Iraq War Dedicating March Programming to College Students Me 13310 6[0] US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream[2] Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference[3] Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2[3] MRI Emerges As Vital Resource in Treatment of Back Pain
...NESS WIRE)--Jun 25, 2007 - Elixir,Pharmaceuticals,...,data highlighting the ability of Glufast(R) (miti...on therapy with metformin, to,manage glucose surge...in the Abstract Book for the American Diabetes,Ass...o, Illinois.,Glufast is an insulin secretagogue th...
...WIRE)--Jun 25, 2007 - CytRx Corporation,(NASDAQ:CY...velopment and commercialization of human therapeut...s from its previously,announced double-blind, plac...l in healthy volunteers with its drug candidate,ar... trial support,the use of arimoclomol in future cl...
Other Medicine Technology:Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 2CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 3CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 4CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 5Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches.
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches.
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches.
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches.
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |